PMID- 35972629
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221129
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 40
IP  - 6
DP  - 2022 Dec
TI  - Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity 
      squamous cell carcinoma: a retrospective study.
PG  - 1282-1289
LID - 10.1007/s10637-022-01293-9 [doi]
AB  - BACKGROUND: Although anti-programmed death receptor-1 (PD-1) agents have been 
      evaluated in the neoadjuvant setting for the treatment of locally advanced head 
      and neck cancer, including oral cavity squamous cell carcinoma (OCSCC), the 
      overall response rate is modest. The aim of the present study was to evaluate the 
      efficacy and safety of neoadjuvant nivolumab in combination with stereotactic 
      body radiotherapy (SBRT) for the treatment of locally advanced OCSCC. METHODS: 
      OCSCC patients who underwent surgical resection within 6 months of treatment with 
      nivolumab plus SBRT from December 2018 to February 2021 were analyzed 
      retrospectively. RESULTS: All 30 eligible patients enrolled in this study well 
      tolerated the neoadjuvant treatment with no serious adverse events (AEs). Of 
      them, 27 patients (90.0%) achieved R0 resection, and 5 patients (16.7%) 
      experienced procedure-associated complications. The complete response (CR), 
      partial response (PR) and stable disease (SD) were 10.0%, 46.7% and 43.3% 
      respectively. The major pathological response (MPR), complete pathological 
      response (pCR) and clinical to pathological downstaging rate were 60.0%, 33.3% 
      and 83.3% respectively. During the median follow-up period of 13.5 months, 26 
      patients (86.7%) who underwent surgical resection remained alive. The 
      disease-free survival (DFS) and overall survival (OS) at 24 months were 70.4% and 
      76.4% respectively. CONCLUSIONS: Neoadjuvant nivolumab plus SBRT is safe and 
      efficacious, and could be used as a potential neoadjuvant option for the 
      treatment of patients with locally advanced OCSCC.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Shen, Peng
AU  - Shen P
AD  - Department of General Internal Medicine, Northern Medical Branch of the PLA 
      General Hospital, Beijing, 100094, People's Republic of China. sppeking@163.com.
FAU - Qiao, Bo
AU  - Qiao B
AD  - Department of Stomatology, The 1st Medical Center of Chinese PLA General 
      Hospital, Beijing, 100853, People's Republic of China.
FAU - Jin, Nenghao
AU  - Jin N
AD  - Department of Stomatology, The 1st Medical Center of Chinese PLA General 
      Hospital, Beijing, 100853, People's Republic of China.
FAU - Wang, Shuyan
AU  - Wang S
AD  - State Key Laboratory of Military Stomatology & National Clinical Research Center 
      for Oral Diseases & Shaanxi Key Laboratory of Stomatology, Department of Oral 
      Medicine, School of Stomatology, The Fourth Military Medical University, Xi'an, 
      Shaanxi, 710032, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20220816
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/therapy
MH  - Radioimmunotherapy
MH  - Nivolumab/adverse effects
MH  - *Carcinoma, Squamous Cell/drug therapy
MH  - *Head and Neck Neoplasms
MH  - *Mouth Neoplasms/drug therapy
OTO - NOTNLM
OT  - Disease-free survival
OT  - Immunotherapy
OT  - Neoadjuvant therapy
OT  - Oral cavity squamous cell carcinoma
OT  - Overall survival
OT  - Radiotherapy
EDAT- 2022/08/17 06:00
MHDA- 2022/11/16 06:00
CRDT- 2022/08/16 11:19
PHST- 2022/05/01 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/08/17 06:00 [pubmed]
PHST- 2022/11/16 06:00 [medline]
PHST- 2022/08/16 11:19 [entrez]
AID - 10.1007/s10637-022-01293-9 [pii]
AID - 10.1007/s10637-022-01293-9 [doi]
PST - ppublish
SO  - Invest New Drugs. 2022 Dec;40(6):1282-1289. doi: 10.1007/s10637-022-01293-9. Epub 
      2022 Aug 16.